Literature DB >> 26415382

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].

T A Bogush, A S Popova, E A Dudko, E A Bogush, A S Tyulyandina, S A Tyulyandin, M I Davydov.   

Abstract

The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single nucleotide polymorphisms of the ERCC1 gene, levels of mRNA or protein) are considered. Data on the prognostic and predictive value of ERCC1 as a marker of the response to platinum-based therapy in ovarian cancer are systematized. The authors discuss the possible causes of heterogeneity of the results and emphasize the necessity of a unified and integrated approach to evaluation of ERCC1 in the tumor. The publications cited in the Search Engine Pub Med up to January 2015 were analyzed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26415382

Source DB:  PubMed          Journal:  Antibiot Khimioter        ISSN: 0235-2990


  4 in total

1.  Digoxin is a selective modifier increasing platinum drug anticancer activity.

Authors:  T A Bogush; V Yu Chernov; E A Dudko; Z S Shprakh; E A Bogush; B E Polotsky; S A Tjulandin; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2016-07-15       Impact factor: 0.788

Review 2.  The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.

Authors:  Dan Gao; James G Herman; Mingzhou Guo
Journal:  Oncotarget       Date:  2016-06-14

3.  Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review.

Authors:  Zulfan Zazuli; Susanne Vijverberg; Elise Slob; Geoffrey Liu; Bruce Carleton; Joris Veltman; Paul Baas; Rosalinde Masereeuw; Anke-Hilse Maitland-van der Zee
Journal:  Front Pharmacol       Date:  2018-09-27       Impact factor: 5.810

4.  UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.

Authors:  Yan Wu; Dan Jin; Xiaohong Wang; Jing Du; Weihua Di; Jiajia An; Cuijie Shao; Jiwei Guo
Journal:  J Oncol       Date:  2019-01-01       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.